Sinopia Biosciences is pioneering a data-driven approach to drug discovery, focusing on the integration of high-throughput multi-omics data, artificial intelligence (AI), and machine learning. The company emphasizes the shift from traditional target-based drug discovery to phenotypic screening, which has proven to be more effective in identifying first-in-class therapeutics. By leveraging advanced technologies that allow for comprehensive measurement of biomolecules, Sinopia can analyze changes across hundreds of thousands of cellular features, providing deeper insights into disease mechanisms and potential therapeutic targets. Their proprietary LEADS® platform combines these elements to facilitate rapid identification of novel drug candidates and mechanisms, particularly in areas with high unmet clinical needs, such as Parkinson's disease.

Additionally, Sinopia is expanding its capabilities through the development of a metabolomics-based high-throughput screening platform. This initiative aims to enhance the understanding of diseases by analyzing metabolites that closely relate to cellular functions. The integration of metabolomics with their existing computational drug discovery framework allows for more accurate and predictive modeling of therapeutic responses. Sinopia's commitment to exploring new therapeutic areas, including oncology and immunology, is supported by significant funding from various research institutions, enabling them to advance their innovative drug discovery efforts.

United States

Sinopia Biosciences is enabling the promise of data-driven drug discovery (D4) by applying high-throughput multi-omics data, AI/machine learning and network analyses, and disease models (genome engineered in vitro models and relevant in vivo models). It is a clinical-stage biotechnology company advancing novel therapeutics derived from its proprietary computational drug discovery platform. Sinopia’s proprietary computational platform combines high-throughput omics data, machine learning, and network biology. Sinopia is headquartered at JLABS San Diego. 

Sinopia Biosciences

Company Details